MedTrace Logo

Childhood Apraxia of Speech: Experience Dependent Changes Induced by Treatment

NCT04832503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2023-10-24

No results posted yet for this study

Summary

Childhood Apraxia of Speech (CAS) is a severe speech-language disorder whose aetiological, neuroanatomical correlates are largely unknown. Furthermore, little is known about the neuroplastic effects induced by different treatment approaches and their relationships with the potential changes in the speech behavioural features that express the core deficit of CAS.

Twenty four children with idiopathic CAS will be enrolled in a multidisciplinary study aimed at analysing the behavioural and neuroanatomical effects of a specific rehabilitative approach, PROMPT (PROMPTs for Restructuring Oral Muscular Phonetic Targets), that employs tactile-kinesthetic-proprioceptive cues vs a traditional speech-language treatment. The children will be allocated in two arms, one receiving a seven month cycle of individual PROMPT treatment, the other a traditional speech and language treatment for the same amount of time.The pre- and post-treatment speech and language performances and DTI and volumetric MR data will be compared in the two groups.

Conditions

  • Childhood Apraxia of Speech

Interventions

BEHAVIORAL

PROMPT- treatment

PROMPTs for Restructuring Oral Muscolar Phonetic Targets

BEHAVIORAL

LNSOM-treatment

Language Non-Speech Oral Motor Treatment

Sponsors & Collaborators

  • Ministry of Health, Italy

    collaborator OTHER_GOV

  • IRCCS Fondazione Stella Maris

    lead OTHER

Principal Investigators

  • Anna Chilosi · IRCCS Stella Maris Foundation

Eligibility

Min Age
4 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-30
Primary Completion
2023-01-30
Completion
2023-03-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04832503 on ClinicalTrials.gov